Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model.
| Autor: | Fakoor MH; Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran., Mousavi Gargari SL; Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran., Owlia P; Molecular Microbiology Research Center, Shahed University, Tehran, Iran., Sabokbar A; Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Infection and drug resistance [Infect Drug Resist] 2020 Jun 09; Vol. 13, pp. 1651-1661. Date of Electronic Publication: 2020 Jun 09 (Print Publication: 2020). |
| DOI: | 10.2147/IDR.S244081 |
| Abstrakt: | Background: Pseudomonas aeruginosa infection is the major cause of death in burn patients. Thus, in this study, a chimeric vaccine harboring the OprF Methodology: Recombinant proteins including the proposed chimer, OprF, OprI, and PcrV were expressed in the E.coli . Mice were immunized with the purified recombinant proteins, and the antibody titre was estimated in the sera obtained from immunized mice. Immunized and control mice were challenged with 2, 5, and 10xLD Results: Results showed that the antibody titre (total IgG) was significantly increased by injection of 10 μg of chimeric protein in the experimental groups compared to the control groups. The antibody survival titre was high until 235 days after administration of the second booster. The survival rate of the mice infected with 10xLD Conclusion: The findings of our study revealed that the chimeric protein is a promising vaccine candidate for control of the P. aeruginosa infection. Competing Interests: The authors report no conflicts of interest in this work. (© 2020 Fakoor et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|